• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Latest

The World Is Investing in Programmable Humans

Like 0

By Lachlann Tierney, Monday, 25 May 2020

Today I want to introduce you to something you probably haven’t heard of before. It’s called synthetic biology, or synbio for short. And it could hold the keys to unlocking the cure to this horrible disease we call COVID-19.

‘Virus fatigue’ is its own type of malady.

I think I speak for most when I say people are sick of the news, sick of the market turmoil, sick of isolation…sick of all the endless loops, really.

But there is a glimmer of hope now.

The US market rallied on Friday due to positive vaccine news from Moderna Inc [NASDAQ:MRNA], which is on a strong run up the charts despite not having a single marketable product:


Source: Tradingview.com

[Click to open in a new window]

MRNA is now a US$25 billion company and is up over 300% in a 12-month window.

It just goes to show how desperate the world is for this to end — panic buys placed on any stock that is even close to the solution.

However, today’s piece isn’t going to go into the tortured market psychology, or which flavour of the month company is winning the race to a vaccine.

Discover the hidden treasures available to everyday investors from this often overlooked sector of the market…Penny Stocks. Download your free report now.

Introducing the next exponential trend in finance…

No, today I want to introduce you to something you probably haven’t heard of before.

It’s called synthetic biology, or synbio for short.

And it could hold the keys to unlocking the cure to this horrible disease we call COVID-19.

Perhaps even more importantly, its emergence could be the dawn of a new era in medicine and health.

Novel drugs, extended life spans, new materials, and advancements in food.

This is a brief definition of what synbio is:

‘Synthetic biology is a new interdisciplinary area that involves the application of engineering principles to biology. It aims at the (re-)design and fabrication of biological components and systems that do not already exist in the natural world. Synthetic biology combines chemical synthesis of DNA with growing knowledge of genomics to enable researchers to quickly manufacture catalogued DNA sequences and assemble them into new genomes.’

It’s a revolutionary new field that is growing rapidly.

Investment is pouring in as you can see below:


Source: Synbiobeta

[Click to open in a new window]

And the investors are the who’s who of the pharmaceutical/financial world…

Moderna is in there, but it also includes Impossible Foods Inc (fake meat company), Bayer, Novartis, Softbank, and DCVC.

ExxonMobil has even invested in a company called Synthetic Genomics Inc, to explore biofuel applications.

Synthetic Genomics also specialises in next-gen vaccines…

Which leads me to my next point.

This could be the end of pandemics

Pandemics became a feature of human life over the millennia as civilisation brought us closer to each other.

The problem is though, we are using centuries-old tools to fight these diseases.

It started in earnest with Edward Jenner’s smallpox vaccine in 1796 and accelerated with Louis Pasteur’s rabies vaccine 1885.

By the 1930s, vaccines for diphtheria, tetanus, anthrax, cholera, plague, typhoid, and tuberculosis came about.

This was followed by vaccines for measles, mumps, and rubella by the mid-20th century.

If you don’t recognise the names of some of these diseases, it’s because the treatment was so successful.

But without a COVID-19 vaccine, we are essentially fighting it with pre-historic medicine.

Largely by staying away from people.

Synbio could be crucial here.

By using computer modelling of the human genome, synbio has the potential to speed up the drug discovery process.

A programmable humanity.

Not just any computers will be set to work on humanity’s problems either.

Increasingly, AI could be behind the latest breakthroughs.

For instance, this little snippet of news from Thursday:

‘Nanome, Inc., a virtual reality (VR) startup whose signature product is a computational chemistry software platform, has co-authored a paper describing 10 potential small molecule inhibitors targeting the SARS-CoV-2 main protease that were generated by artificial intelligence (AI).’

Despite the technical language, AI-generated medicine is the punchline.

[conversion type=”in_post”]

Technology the only option

As a result, synbio stands at the intersection of some major exponential trends.

In addition to being its own exponential trend.

It sounds dangerous and could have ethical ramifications, but it looks like it is the future we will soon be living in.

Personally, I generally have a dim view of human nature.

I think the world’s problems are unlikely to be solved simply by increasing the amount of moral fibre in our daily diet of media, politics, and the like.

Technology can be a panacea here. A literal panacea.

Not because it’s the most desirable option, but because it’s the only one available.

In the coming weeks you will hear more from us on the themes discussed today. We hope you stick around.

Regards,

Lachlann Tierney,
For Money Morning

PS: We believe these rapid fire market opportunities are a fantastic way to grow your wealth. Which is why you’ll find us talking about the big trends that can uncover them. If that is something up your investment alley, then click here to learn more.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney
Lachlann ‘Lachy’ Tierney is passionate about uncovering hidden opportunities in the microcap sector. With four years of experience as a senior equities analyst at one of Australia’s leading microcap firms, he has built a reputation for rigorous research, deep-dive due diligence, and accessible investor communications. Over this time, he has vetted seed, pre-IPO and ASX-listed companies across sectors, conducted onsite visits, and built strong relationships across the microcap space. Lachy is nearing completion of a PhD in economics at RMIT University, where his research focuses on blockchain governance and voting systems. His work is housed within the Blockchain Innovation Hub at RMIT, a leading research centre for crypto-economics and blockchain research. He holds a Master’s degree from the London School of Economics and an Honours BA in Philosophy and Politics from the University of Melbourne. Born in New York and raised in California, Lachy grew up a few blocks from biotech giant Amgen and counts among his peers various characters in the overlapping worlds of venture capital, technology and crypto. When he’s not researching microcaps, he’s most likely sweating it out in a sauna or dunking himself in cold Tasmanian water.

Lachlann’s Premium Subscriptions

Publication logo
Australian Small-Cap Investigator
Publication logo
Fat Tail Microcaps
Publication logo
James Altucher’s Early-Stage Crypto Investor Australia

Latest Articles

  • Bitcoin’s Identity Crisis
    By Charlie Ormond

    The new Fed nominee has called Bitcoin a ‘sustainable store of value,’ and the 'new gold' for anyone under 40. So why isn't Bitcoin surging? The answer reveals something important about what Bitcoin is in this moment, and whether it belongs in your portfolio.

  • Market Volume Turns up to Eleven
    By Murray Dawes

    As predicted last week, a sharp correction has begun in markets with gold, silver, and bitcoin plummeting. The plunge in software stocks is turning the volume up to eleven, so it’s time to hunt for opportunities.

  • Oil Services: The Leveraged Play on Energy’s Next Move
    By James Cooper

    Oil prices may be stuck, but service stocks aren’t. Here’s how I’m using technical analysis to capture early gains in this sector.

Primary Sidebar

Latest Articles

  • Bitcoin’s Identity Crisis
  • Market Volume Turns up to Eleven
  • Oil Services: The Leveraged Play on Energy’s Next Move
  • The RBA Goes It Alone
  • China Capitulation Part 4 – The purge that ends the dream of a China reunification

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2026 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988